Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ARDX
- CUSIP: N/A
- Web: www.ardelyx.com
Capitalization:- Market Cap: $272.47 million
- Outstanding Shares: 47,386,000
Average Prices:- 50 Day Moving Avg: $5.09
- 200 Day Moving Avg: $10.16
- 52 Week Range: $4.05 - $16.30
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.63
- P/E Growth: -0.07
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $3.54 per share
- Price / Book: 1.62
Profitability:- EBIDTA: ($116,220,000.00)
- Return on Equity: -64.57%
- Return on Assets: -58.64%
Debt:- Current Ratio: 9.22%
- Quick Ratio: 9.22%
Misc:- Average Volume: 480,681 shs.
- Beta: 0.17
- Short Ratio: 1.88
Frequently Asked Questions for Ardelyx (NASDAQ:ARDX)
What is Ardelyx's stock symbol?
Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."
How were Ardelyx's earnings last quarter?
Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings data on Friday, May, 5th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.06. View Ardelyx's Earnings History.
When will Ardelyx make its next earnings announcement?
Where is Ardelyx's stock going? Where will Ardelyx's stock price be in 2017?
5 brokers have issued twelve-month price objectives for Ardelyx's shares. Their forecasts range from $12.00 to $24.00. On average, they anticipate Ardelyx's share price to reach $15.60 in the next twelve months. View Analyst Ratings for Ardelyx.
What are analysts saying about Ardelyx stock?
Here are some recent quotes from research analysts about Ardelyx stock:
- 1. According to Zacks Investment Research, "Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. Ardelyx, Inc. is headquartered in Fremont, California. " (7/18/2017)
- 2. Cantor Fitzgerald analysts commented, "T3MPO-1 is a Relevant Trial. The results of the trial, disclosed May 12, yielded a statistically significant outcome in the primary endpoint and in seven of eight secondary endpoints. However, the results showed a less-than-expected benefit, in our view, with 27% of tenapanor-treated patients achieving the primary endpoint versus 18.7% for placebo (p=0.02), although the responder rate was less than was observed in the Phase IIb study." (5/31/2017)
Are investors shorting Ardelyx?
Ardelyx saw a increase in short interest in June. As of June 15th, there was short interest totalling 1,326,783 shares, an increase of 31.5% from the May 31st total of 1,008,745 shares. Based on an average daily volume of 579,916 shares, the days-to-cover ratio is presently 2.3 days. Approximately 4.4% of the company's shares are sold short.
Who are some of Ardelyx's key competitors?
Some companies that are related to Ardelyx include Intra-Cellular Therapies (ITCI), Aurinia Pharmaceuticals (AUPH), Sucampo Pharmaceuticals (SCMP), CytomX Therapeutics (CTMX), Dynavax Technologies Corporation (DVAX), MyoKardia (MYOK), Atara Biotherapeutics (ATRA), Progenics Pharmaceuticals (PGNX), Geron Corporation (GERN), Karyopharm Therapeutics (KPTI), Jounce Therapeutics (JNCE), BioCryst Pharmaceuticals (BCRX), Bellicum Pharmaceuticals (BLCM), Ignyta (RXDX), BioSpecifics Technologies Corp (BSTC), Ra Pharmctl (RARX), Merus NV (MRUS) and BioTime (BTX).
Who are Ardelyx's key executives?
Ardelyx's management team includes the folowing people:
- David M. Mott, Independent Chairman of the Board
- Michael G. Raab, President, Chief Executive Officer, Director
- Mark E. Kaufmann, Chief Financial Officer
- Reginal Seeto, Chief Operating Officer, Executive Vice President
- Jeremy S. Caldwell Ph.D., Executive Vice President, Chief Scientific Officer
- Paul Korner M.D., Executive Vice President, Chief Medical Officer
- Elizabeth Grammer Esq., Senior Vice President, General Counsel
- David P. Rosenbaum Ph.D., Chief Development Officer
- Robert H. Bazemore Jr., Independent Director
- William C. Bertrand Jr. Esq., Independent Director
How do I buy Ardelyx stock?
Shares of Ardelyx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ardelyx's stock price today?
One share of Ardelyx stock can currently be purchased for approximately $5.75.
MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Ardelyx (NASDAQ:ARDX)Earnings History by Quarter for Ardelyx (NASDAQ ARDX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2017 | | ($0.64) | | | | | N/A |  |
| 5/5/2017 | Q1 2017 | ($0.65) | ($0.59) | | | View | N/A | |
| 2/17/2017 | Q4 2016 | ($0.66) | ($0.66) | | | View | N/A | |
| 11/7/2016 | Q316 | ($0.74) | ($0.65) | | | View | Listen | |
| 8/8/2016 | Q216 | ($0.75) | ($0.83) | | | View | N/A | |
| 5/9/2016 | Q116 | ($0.66) | ($0.70) | | | View | N/A | |
| 3/4/2016 | Q4 | ($0.82) | ($0.65) | | | View | N/A | |
| 11/12/2015 | Q315 | ($0.48) | ($0.70) | | | View | Listen | |
| 8/12/2015 | Q215 | $0.09 | $0.42 | $25.87 million | $17.70 million | View | Listen | |
| 5/12/2015 | Q1 | ($0.02) | ($0.19) | $9.65 million | $5.88 million | View | N/A | |
| 2/25/2015 | Q4 2014 | ($0.06) | ($0.21) | $8.15 million | $6.34 million | View | Listen | |
| 8/7/2014 | Q2 2014 | $1.83 | $0.44 | $8.10 million | $9.14 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ardelyx (NASDAQ:ARDX)2017 EPS Consensus Estimate: ($2.57)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.65) | ($0.65) | ($0.65) |
| Q2 2017 | 1 | ($0.63) | ($0.63) | ($0.63) |
| Q3 2017 | 1 | ($0.66) | ($0.66) | ($0.66) |
| Q4 2017 | 2 | ($0.70) | ($0.56) | ($0.63) |
(Data provided by Zacks Investment Research)
Dividend History for Ardelyx (NASDAQ:ARDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ardelyx (NASDAQ:ARDX)Insider Ownership Percentage: 15.46%
Institutional Ownership Percentage: 83.63%
Insider Trades by Quarter for Ardelyx (NASDAQ:ARDX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/18/2017 | David P. Rosenbaum | Insider | Sell | 2,051 | $11.98 | $24,570.98 | |
| 3/3/2017 | Jeremy S. Caldwell | EVP | Sell | 1,026 | $14.14 | $14,507.64 | |
| 12/16/2016 | David P Rosenbaum | SVP | Sell | 900 | $14.48 | $13,032.00 | |
| 10/11/2016 | Jeffrey W. Jacobs | SVP | Sell | 6,000 | $15.00 | $90,000.00 | |
| 9/23/2016 | Elizabeth A Grammer | SVP | Sell | 5,000 | $12.00 | $60,000.00 | |
| 9/19/2016 | Elizabeth A. Grammer | SVP | Sell | 6,859 | $11.21 | $76,889.39 | |
| 7/18/2016 | Nea 15 Gp, Llc | Major Shareholder | Buy | 1,527,301 | $8.73 | $13,333,337.73 | |
| 3/21/2016 | Gordon Ringold | Director | Buy | 15,000 | $7.77 | $116,550.00 | |
| 1/13/2016 | Nea 15 Gp, Llc | Major Shareholder | Buy | 1,000,000 | $10.00 | $10,000,000.00 | |
| 11/27/2015 | Jeffrey W. Jacobs | SVP | Sell | 2,000 | $20.00 | $40,000.00 | |
| 10/8/2015 | Jeffrey W. Jacobs | SVP | Sell | 2,000 | $19.88 | $39,760.00 | |
| 9/22/2015 | David P. Rosenbaum | SVP | Sell | 1,400 | $22.05 | $30,870.00 | |
| 9/15/2015 | David P Rosenbaum | SVP | Sell | 2,540 | $22.01 | $55,905.40 | |
| 9/10/2015 | Jeffrey W. Jacobs | SVP | Sell | 2,000 | $20.59 | $41,180.00 | |
| 9/8/2015 | Michael Raab | CEO | Sell | 9,785 | $20.29 | $198,537.65 | |
| 9/3/2015 | David P Rosenbaum | SVP | Sell | 2,537 | $18.78 | $47,644.86 | |
| 7/22/2015 | Elizabeth A Grammer | VP | Sell | 2,500 | $18.00 | $45,000.00 | |
| 7/15/2015 | Elizabeth A Grammer | VP | Sell | 10,000 | $17.12 | $171,200.00 | |
| 6/10/2015 | Gordon Ringold | Director | Buy | 10,000 | $15.19 | $151,900.00 | |
| 6/5/2015 | Enterprise Associates 12 New | Major Shareholder | Buy | 1,869,159 | $10.70 | $20,000,001.30 | |
| 6/5/2015 | Peter G Schultz | Director | Buy | 46,729 | $10.70 | $500,000.30 | |
| 5/4/2015 | Mark Kaufmann | CFO | Sell | 9,083 | $10.81 | $98,187.23 | |
| 4/6/2015 | Mark Kaufmann | CFO | Sell | 7,681 | $12.80 | $98,316.80 | |
| 3/2/2015 | Elizabeth A Grammer | VP | Sell | 1,737 | $15.81 | $27,461.97 | |
| 2/4/2015 | Jeffrey W Jacobs | VP | Sell | 8,888 | $16.28 | $144,696.64 | |
| 1/8/2015 | Ventures Vii Lp Cmea | Major Shareholder | Sell | 300,000 | $24.25 | $7,275,000.00 | |
| 12/26/2014 | Scott D Sandell | Major Shareholder | Sell | 1,972 | $21.28 | $41,964.16 | |
| 6/24/2014 | Ventures Vii Lp Cmea | Major Shareholder | Buy | 316,826 | $14.00 | $4,435,564.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ardelyx (NASDAQ:ARDX)
Latest Headlines for Ardelyx (NASDAQ:ARDX)
| Source: |
|
| Date | Headline |
|---|
 | Ardelyx, Inc. (NASDAQ:ARDX) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 18 at 4:56 PM |
| Ardelyx, Inc. (ARDX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 14 at 1:32 PM |
 | Catalyst (CPRX) Shows Strength: Stock Adds 9.6% in Session
www.zacks.com - July 12 at 4:29 PM |
| Ardelyx, Inc. (ARDX) Expected to Post Earnings of -$0.63 Per Share
www.americanbankingnews.com - July 12 at 8:30 AM |
 | Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant
finance.yahoo.com - July 10 at 3:58 PM |
| Ardelyx, Inc. (ARDX) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - July 9 at 12:40 AM |
| 5 Breakout Stocks Offering Phenomenal Returns
finance.yahoo.com - July 8 at 6:22 AM |
| Ardelyx, Inc. (ARDX) Short Interest Up 31.5% in June
www.americanbankingnews.com - June 30 at 7:14 AM |
| Ardelyx, Inc. (ARDX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 19 at 8:34 AM |
| Ardelyx, Inc. (ARDX) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - June 13 at 12:28 AM |
| Ardelyx Inc (ARDX) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - May 31 at 7:36 AM |
| With Ardelyx's Fall, Does Synergy Now Have a Clear Path to Victory?
finance.yahoo.com - May 29 at 3:58 PM |
| Ardelyx Inc (ARDX) Given New $12.00 Price Target at BTIG Research
www.americanbankingnews.com - May 27 at 11:16 PM |
| Zacks Investment Research Upgrades Ardelyx Inc (ARDX) to Buy
www.americanbankingnews.com - May 23 at 4:24 PM |
| Ardelyx Inc (ARDX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 23 at 8:36 AM |
| Ardelyx Inc (ARDX) Forecasted to Post FY2017 Earnings of ($2.84) Per Share
www.americanbankingnews.com - May 22 at 7:22 AM |
| -$0.63 Earnings Per Share Expected for Ardelyx Inc (ARDX) This Quarter
www.americanbankingnews.com - May 19 at 1:20 PM |
| Ardelyx Inc (ARDX) Earns "Overweight" Rating from Cantor Fitzgerald
www.americanbankingnews.com - May 19 at 10:52 AM |
| Ardelyx Inc (ARDX) Given "Buy" Rating at Citigroup Inc
www.americanbankingnews.com - May 15 at 3:50 PM |
| Short Interest in Ardelyx Inc (ARDX) Decreases By 10.7%
www.americanbankingnews.com - May 15 at 8:48 AM |
 | AZN's PACIFIC Proves To Have Depth, ARDX Abuzz, No Flashy Data From ALLSTAR
www.nasdaq.com - May 14 at 3:42 PM |
 | Ardelyx (ARDX) Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C Meets Primary Endpoint
www.streetinsider.com - May 12 at 9:13 PM |
| Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
finance.yahoo.com - May 12 at 4:11 PM |
| Ardelyx Inc (ARDX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - May 11 at 10:52 PM |
| Wedbush Analysts Boost Earnings Estimates for Ardelyx Inc (ARDX)
www.americanbankingnews.com - May 11 at 9:16 AM |
| Ardelyx Inc (ARDX) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 3:36 PM |
| Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress
finance.yahoo.com - May 5 at 3:38 PM |
| Ardelyx reports 1Q loss
finance.yahoo.com - May 5 at 3:38 PM |
| Somewhat Critical Press Coverage Somewhat Likely to Impact Ardelyx (ARDX) Share Price
www.americanbankingnews.com - May 2 at 5:28 PM |
| Analysts Anticipate Ardelyx Inc (ARDX) to Announce -$0.61 Earnings Per Share
www.americanbankingnews.com - April 28 at 11:36 AM |
| Ardelyx (ARDX) Getting Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 28 at 10:24 AM |
| Ardelyx Inc (ARDX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 25 at 6:16 PM |
| Somewhat Negative Media Coverage Somewhat Likely to Affect Ardelyx (ARDX) Share Price
www.americanbankingnews.com - April 25 at 1:08 PM |
| Ardelyx (ARDX) Receives Daily News Impact Rating of -0.12
www.americanbankingnews.com - April 22 at 10:22 AM |
| Ardelyx Inc (ARDX) Insider David P. Rosenbaum Sells 2,051 Shares
www.americanbankingnews.com - April 21 at 9:30 PM |
| Ardelyx To Present at Upcoming Spring Medical Meetings
finance.yahoo.com - April 18 at 9:11 AM |
| Ardelyx (ARDX) Receives Media Sentiment Rating of 0.56
www.americanbankingnews.com - April 13 at 8:26 AM |
| Analysts Anticipate Ardelyx Inc (ARDX) Will Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 9 at 9:44 AM |
| -$0.61 EPS Expected for Ardelyx Inc (ARDX) This Quarter
www.americanbankingnews.com - April 7 at 5:35 PM |
| ARDELYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 9 at 9:13 PM |
| Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
finance.yahoo.com - February 28 at 10:14 AM |
| Wedbush Has A New Best Idea For 2017: Ardelyx
finance.yahoo.com - February 23 at 3:37 PM |
| ARDELYX, INC. Financials
finance.yahoo.com - February 23 at 3:37 PM |
| Ardelyx reports 4Q loss - Yahoo Finance - Yahoo Finance
finance.yahoo.com - February 18 at 3:34 PM |
 | Blog Coverage Ardelyx Reports Positive Data for the Treatment for Hyperphosphatemia in Patients with End-Stage Renal disease
us.rd.yahoo.com - February 17 at 6:32 PM |
| Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - February 17 at 6:32 PM |
| ARDELYX, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - February 17 at 6:32 PM |
| Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
us.rd.yahoo.com - February 16 at 8:41 PM |
| Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
us.rd.yahoo.com - February 16 at 8:41 PM |
| 6:31 am Ardelyx reports its Phase 3 trial evaluating tenapanor as a treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis met its primary endpoint and was generally well-tolerated
us.rd.yahoo.com - February 16 at 8:41 PM |
Ardelyx (ARDX) Chart for Wednesday, July, 26, 2017
